Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer

Description

The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man's risk of cancer, together with multiparametric magnetic resonance imaging (mpMRI) to identify men with higher grade cancer. The main questions it aims to answer are: * If genetic data related to prostate cancer used with MRI can identify higher-grade, potentially fatal prostate cancer * What age a MRI is useful clinically for prostate cancer screening * If deep learning methods used with MRI when the genetic risk of the man is known can more accurately predict significant cancers Participants will: * Get a prostate specific antigen (PSA) blood test * Get an mpMRI * Get the results of their genetic data to determine if they are considered high-, intermediate-, or low-risk for prostate cancer based on the trials genetic testing * Follow-up for this trial based on the participants risk and findings from the PSA test and mpMRI

Conditions

Prostate Cancer, Polygenic Risk Score

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man's risk of cancer, together with multiparametric magnetic resonance imaging (mpMRI) to identify men with higher grade cancer. The main questions it aims to answer are: * If genetic data related to prostate cancer used with MRI can identify higher-grade, potentially fatal prostate cancer * What age a MRI is useful clinically for prostate cancer screening * If deep learning methods used with MRI when the genetic risk of the man is known can more accurately predict significant cancers Participants will: * Get a prostate specific antigen (PSA) blood test * Get an mpMRI * Get the results of their genetic data to determine if they are considered high-, intermediate-, or low-risk for prostate cancer based on the trials genetic testing * Follow-up for this trial based on the participants risk and findings from the PSA test and mpMRI

Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer

Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer

Condition
Prostate Cancer
Intervention / Treatment

-

Contacts and Locations

Washington

Howard University Hospital, Washington, District of Columbia, United States, 20060

Bethesda

National Cancer Institute, Bethesda, Maryland, United States, 20814

Bethesda

Walter Reed National Military Medical Center, Bethesda, Maryland, United States, 20814

Boston

Brigham and Women's Hospital, Boston, Massachusetts, United States, 02155

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * They must have the ability to understand and the willingness to sign a written information consent document.
  • * Estimated life expectancy of greater than 10 years.
  • * No history of prostate cancer.
  • * Participants must be between 40-69 years of age. This is the age at which screening for prostate cancer is recommended. This is due to younger patients not being at risk for the disease and older patients not benefiting from diagnosis.
  • * No biopsy for prostate cancer within the past 5 years.
  • * No prostate MRI within the past 5 years.
  • * Unwillingness to sign the informed consent form.
  • * Contraindication to biopsy such as uncorrectable bleeding or coagulation disorder.
  • * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit the safety of a biopsy and/or surgery.
  • * Unable to undergo an MRI.

Ages Eligible for Study

40 Years to 69 Years

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Adam S. Kibel, MD,

Adam S Kibel, MD, MHCM, STUDY_CHAIR, Brigham and Women's Hospital

Peter Pinto, MD, STUDY_CHAIR, National Cancer Institute (NCI)

Study Record Dates

2030-04-30